Device type · LOJ
Kit, Test,Alpha-Fetoprotein For Testicular Cancer
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
LOJ
Immunology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
11
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Kit, Test,Alpha-Fetoprotein For Testicular Cancer
- Product code
- LOJ
- Device class
- Class II
- Review panel
- Immunology
- Regulation
- 21 CFR 866.6010
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LOJ
Latest FDA decisions
- Elecsys AFP510(k)
K220176 · Decided Sep 15, 2022 · 237 days after receipt
Device type: Kit, Test,Alpha-Fetoprotein For Testicular Cancer (LOJ) · Laboratory Medicine & Pathology
- VITROS AFP510(k)
K213626 · Decided Jun 15, 2022 · 210 days after receipt
Device type: Kit, Test,Alpha-Fetoprotein For Testicular Cancer (LOJ) · Laboratory Medicine & Pathology
Reports received
11
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
11
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 2 | 0 | 0 | 0 |
| Apr 24 | 1 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 1 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 2 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 1 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 1 | 0 | 0 | 0 |
| Jun 26 | 1 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 8 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results8
- Low Test Results4
- Non Reproducible Results2
1 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions8
- Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available2
- Insufficient Information1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2065-2018 · Started Mar 5, 2018
Reason given: Asfotase Alfa (Strensiq) interferes with certain Tosoh assays which potentially causes falsely increased or falsely decreased immunoassay test results, depending upon the assay.
Cause as FDA categorized it: Device Design
Z-2145-2016 · Started May 9, 2016
Reason given: Ortho Clinical Diagnostics (OCD) confirmed that specific lots of VITROS Immunodiagnostic Products AFP Reagent Pack product exhibit an increase in the reaction signal over time potentially resulting in the inability to calibrate and use the product.
Cause as FDA categorized it: Nonconforming Material/Component
Z-1626-2011 · Started Dec 22, 2010 · Posted by FDA Mar 11, 2011
Reason given: Product labels indicate that the products are for IVD use and they do not have an approved 510(k).
Cause as FDA categorized it: PMA
4 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.